Clinical Trials Logo

Clinical Trial Summary

Patients treated in Palliative Care Units are potentially fragile patients, especially in our case, which are cancer patients. The management of these patients is usually done from experience, because these patients rarely meet criteria for clinical trials, as their inclusion could affect results obtained in the trial.

There is insufficient clinical information on the quality of life of cancer patients with breakthrough pain treated in palliative care units according to routine clinical practice. For this reason we consider it is appropriate to prospectively evaluate the quality of life of cancer patients with cancer breakthrough pain treated in palliative care units as well as the characteristics of these patients.

This post-authorization observational study will assess the quality of life of patients with breakthrough cancer pain treated in Palliative Care Units in Spanish hospitals.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02840500
Study type Observational
Source Angelini Farmacéutica
Contact
Status Completed
Phase N/A
Start date June 27, 2016
Completion date March 2018

See also
  Status Clinical Trial Phase
Completed NCT00994760 - Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years N/A
Not yet recruiting NCT05531422 - Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP Phase 2
Completed NCT01842893 - Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer Phase 3
Completed NCT02886286 - Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain Phase 4
Completed NCT02869321 - Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Phase 4
Completed NCT02437929 - Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment N/A
Completed NCT00236145 - Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain Phase 3
Completed NCT02836379 - Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent N/A
Active, not recruiting NCT02278601 - Comparison of Regimens MPIB, CIPCEA, PCEA Phase 3
Terminated NCT00842829 - Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients Phase 4
Recruiting NCT05200806 - A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy Phase 4
Withdrawn NCT03809455 - Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients Phase 2
Completed NCT03435120 - Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
Completed NCT02050503 - Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis N/A
Terminated NCT00387010 - Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain Phase 3
Withdrawn NCT05053308 - Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement N/A
Recruiting NCT04011150 - Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour Phase 3
Terminated NCT01901718 - An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray. N/A
Completed NCT00402350 - Staccato Fentanyl Single and Multidose PK Phase 1
Completed NCT00236041 - Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP) Phase 2